Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy

This publication has 41 references indexed in Scilit:

• Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials
  Journal of Clinical Oncology, 2005
• Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesisImplications for cellular surrogate marker analysis of antiangiogenesis
  Cancer Cell, 2005
• A surrogate marker to monitor angiogenesis at last
  Cancer Cell, 2005
• A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens
  Cancer Research, 2004
• The anti-angiogenic basis of metronomic chemotherapy
  Nature Reviews Cancer, 2004
• Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
  Science, 2002
• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
  Annals of Oncology, 2002
• Metronomic scheduling: the future of chemotherapy?
  The Lancet Oncology, 2001
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
  Journal of Clinical Investigation, 2000
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
  Nature, 1993